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Increases in matrix metalloproteinases (MMPs) at atherosclerotic lesions are involved in the migration of smooth muscle cells (SMCs) into the
intima and to the rupture of plaques, being implicated in the progression of atherosclerosis. The present study examined themechanisms underlying the
production of MMP-1, interstitial collagenase-1, induced by oxidized low-density lipoprotein (oxLDL) and 4-hydroxynonenal (4-HNE), factors
proposed to play a pivotal role in atherogenesis, in human coronary SMCs. oxLDL promoted the production of MMP-1 with the preceding
phosphorylation of extracellular signal-regulated kinase (ERK) 1/2. Immunoprecipitation of platelet-derived growth factor receptor β (PDGFR-β)
revealed that oxLDL induced tyrosine phosphorylation of the receptor. Inhibition of the activation of PDGFR-β and ERK1/2 resulted in a suppression
of the production ofMMP-1.Consistently, 4-HNEalso elicited the production ofMMP-1with the preceding phosphorylation of PDGFR-β andERK1/
2. The 4-HNE-induced production ofMMP-1was preventedwhen the activation of PDGFR-β and ERK1/2was inhibited. The present results suggest
that the activation of PDGFR-β and ERK1/2 is involved in the production of MMP-1 in oxLDL- and 4-HNE-stimulated human coronary SMCs.
© 2006 Elsevier B.V. All rights reserved.Keywords: Matrix metalloproteinase; Oxidized LDL; Platelet-derived growth factor receptor; Smooth muscle cell1. Introduction
Atherosclerosis develops and progresses in association with
the oxidation of low-density lipoprotein (LDL) and the
accumulation of the oxidized LDL (oxLDL) within the arterial
wall [1,2]. oxLDL triggers numerous biological responses
including the transformation of macrophages into lipid-laden
foam cells and the migration of vascular smooth muscle cells
(SMCs) into the intima [3–5]. These oxLDL-promoted cellular
responses lead to the accumulation and subsequent necrosis of
foam cells followed by the development of a lipid core, and toAbbreviations: ERK, extracellular signal-regulated kinase; 4-HNE, 4-
hydroxynonenal; LDL, low-density lipoprotein; MMP, matrix metalloprotei-
nase; oxLDL, oxidized LDL; PDGF, platelet-derived growth factor; PDGFR,
PDGF receptor; ROS, reactive oxygen species; RT-PCR, reverse transcription-
polymerase chain reaction; SMC, smooth muscle cell; hCSMC, human coronary
SMC
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doi:10.1016/j.bbamcr.2006.06.003the formation of fibrous caps composed of intimal SMCs and
extracellular matrix components to cover the lipid core, resulting
in the formation of atherosclerotic plaques. In the advanced
stages of atherosclerosis, the thickness of the fibrous caps
decreases with the degradation of components of the extra-
cellular matrix, leading to the formation of vulnerable plaques
that are susceptible to rupture. The disruption of the plaques
triggers the formation of a thrombus, which is the cause of acute
coronary syndromes [4–6]. Thus, oxLDL plays a critical role in
atherogenesis. The biological activities of oxLDL are in part
mediated by various components present in oxLDL particles
including oxysterols, lysophosphatidylcholine, oxidized phos-
pholipids, and aldehydes such as 4-hydroxynonenal (4-HNE)
[7–9].
During the course of atherosclerosis, the migration of
SMCs and the rupture of plaques are associated with the
degradation of extracellular matrix proteins, such as collagen
and fibronectin, catalyzed by matrix metalloproteinases
(MMPs) [6,10–12]. The more than 20 types of MMPs
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collagenases (MMP-1, -8, and -13), gelatinases (MMP-2 and
-9), stromelysins (MMP-3, -10, and -11), membrane-type
MMPs (MMP-14, -15, -16, -17, -24, and -25), and matrilysins
(MMP-7 and -26) [13]. The expression ofMMP-1, -2, -3, -7, -8,
-9, -13, and -14 is increased at atherosclerotic lesions including
the shoulder region of vulnerable plaques in human and animal
models [10,14–18]. Among the MMPs, collagenases cleave
native collagen types I and III, predominant structural
components of atherosclerotic lesions, while other MMPs,
such as gelatinases, can degrade the collagenase-generated
fragments only, indicating that an increase in collagenases is a
critical event in the progression of atherosclerosis.
In atherosclerotic lesions, MMP-1 localizes mainly with
SMCs [14,15] and macrophages [14,16] while MMP-8 and -13
are expressed by neutrophils [17] and macrophages [16],
respectively. Several cytokines have been shown to stimulate
the expression of MMP-1 in SMCs and macrophages [19–22].
However, little is known about the contribution of oxLDL and
bioactive oxidized lipids including 4-HNE to the production of
MMP-1, although oxLDL is reported to increase MMP-1 levels
in human umbilical vein and aortic endothelial cells [23], MMP-
9 levels in human monocyte-derived macrophages [24], and
MMP-14 levels in human saphenous vein SMCs [25]. In the
present study, therefore, we examined the possible involvement
of oxLDL and 4-HNE in the production of MMP-1 and the
intracellular signaling responsible for the production in human
coronary SMCs (hCSMCs).
2. Materials and methods
2.1. Materials
Antibodies against extracellular signal-regulated kinase (ERK) 1/2, phos-
phorylated ERK1/2, platelet-derived growth factor receptor β (PDGFR-β, sc-
432), and phosphorylated tyrosine residue of PDGFR-β (sc-17173), and protein
A-agarose were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA). The antibody against platelet-derived growth factor (PDGF) BB and/or AA
(Catalog number, AB-20-NA; Lot number, N09) was from R&D Systems, Inc.
(Minneapolis, MN). PD98059, 4-HNE, AG1295, and AG1478 were from
Calbiochem (La Jolla, CA). Human native LDL (BT-903) was from Biomedical
Technologies Inc. (Stoughton, MI), the anti-MMP-1 antibody was from Sigma
(St. Louis, MO), and 2′,7′-dichlorodihydrofluorescein (DCFH) diacetate was
from Molecular Probes, Inc. (Eugene, OR). All other reagents were obtained
from Wako Pure Chemical Industries (Osaka, Japan).
2.2. Cell culture
hCSMCs (Cambrex Bio Science Walkersville, Inc., Walkersville, MD)
were cultured in MCDB131 medium supplemented with 5% heat-inactivated
fetal bovine serum, 1 ng/ml basic fibroblast growth factor, 0.5 ng/ml
epidermal growth factor, 5 μg/ml insulin, 100 units/ml penicillin, and 100 μg/
ml streptomycin in collagen (type I)-coated culture dishes (Asahi Techno
Glass, Corp. Japan). The cells, between the 6th and 8th passages, were plated
in 35-mm dishes at 2×105 cells in MCDB131 medium, and placed in fresh
medium.
2.3. Preparation of oxLDL
The oxidation of LDL was performed as described previously [26]. Briefly,
human native LDL (2.5 mg protein/ml) was oxidized with 10 μM CuSO4 at37 °C for 3 h, and dialyzed against phosphate-buffered saline containing
200 μM EDTA at 4 °C. The oxLDL contained 10–15 nmol thiobarbituric acid-
reactive substances (TBARS)/mg protein, while native LDL (before oxidation)
contained 0.6–1.2 nmol TBARS/mg protein. The relative electrophoretic
mobility of the oxLDL was about 1.4 as compared with that of native LDL.
2.4. Immunoblot analysis
hCSMCswere treated and stimulated with various reagents including oxLDL
and 4-HNE, as described in the figure legends. The extracellular medium and
cells, as samples, were subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis on a 10% gel. The separated proteins were transferred onto a
nitrocellulose membrane. Antibodies against MMP-1, ERK1/2, and phosphory-
lated ERK1/2 were applied. The bound antibodies were visualized using a
peroxidase-conjugated secondary antibody and enhanced chemiluminescence
Western blotting detection reagents (Amersham Pharmacia Biotech). Represen-
tative results of three separate experiments are shown. To estimate the amounts
of MMP-1, the density of each band on a film was analyzed using a film scanner
and NIH image analysis software. The results are expressed in arbitrary units
(mean±SEM, n=3).
2.5. Immunoprecipitation of PDGFR-β
hCSMCs were incubated with genistein or AG1295 for 1 h in the presence of
5 mM Na3VO4, and stimulated with oxLDL or 4-HNE as described in the figure
legends. After being washed, the cells were lysed and subjected to
immunoprecipitation of PDGFR-β as described previously [27]. The lysate
was incubated with anti-PDGFR-β antibodies overnight at 4 °C and further with
protein A-agarose for 3 h. After centrifugation, the pellet was subjected to
immunoblot analysis (a 5% gel) using antibodies against PDGFR-β or the
phosphorylated tyrosine residue of PDGFR-β. Representative results of three
separate experiments are shown. To estimate the phosphorylation of PDGFR-β,
the density of the bands for PDGFR-β and its phosphorylated form on a film was
analyzed as above. Results are adjusted for PDGFR-β levels and expressed in
arbitrary units (mean±SEM, n=3).
2.6. Zymography and collagenase activity
After stimulation with oxLDL, the extracellular medium was subjected to
zymography to detect MMP-1 using a casein (1 mg/ml)-containing 12%
ZymogramGel (Invitrogen). Zymographywas carried out by treatment of the gel
with NOVEX Zymogram renaturing buffer and NOVEX Zymogram developing
buffer (Invitrogen). The gel was stained with Coomassie Brilliant Blue R-250.
Collagenase activity was determined with FITC-labeled collagen (type I) as a
fluorogenic substrate using a commercial assay kit (Cosmo Bio, Japan). Briefly,
the extracellular medium was treated with 0.9 mM 4-aminophenylmercuric
acetate at 37 °C for 10 min to activate MMP-1, and further incubated with the
substrate for 3 h. After centrifugation of the mixture, the fluorescence intensity in
the supernatant was measured with a spectrofluorometer (F-2000, Hitachi), with
excitation at 495 nm and emission at 520 nm. One unit of the enzymatic activity
represents the degradation of 1 μg of collagen per min.
2.7. Reverse transcription-polymerase chain reaction (RT-PCR)
The expression of transcripts for MMP-1 was analyzed by RT-PCR. After
stimulation of hCSMCswith oxLDL, total RNAwas extracted from the cells with
ISOGEN (NIPPON GENE Co., Ltd., Tokyo, Japan). First-strand cDNA was
generated from the total RNA in a reaction mixture containing random ninemers,
dNTP, RNase inhibitor, and ReverTra Ace (TOYOBO, Co. Ltd., Osaka, Japan).
The resulting reaction mixture was subjected to PCR with AmpliTaq Gold
(Applied Biosystems) using the following primers: 5′-GATCATCGGGA-
CAACTCTCCT (sense) and 5′-TCCGGGTAGAAGGGATTTGTG (antisense)
for MMP-1, 5′-CAAGACCAGGACGGTCATTT (sense) and 5′-ACATC-
CATGTCCCAGGAAAG (antisense) for PDGF-AA, 5′-CGAGTTGGACCT-
GAACATGA (sense) and 5′-GTCACCGTGGCCTTCTTAAA (antisense) for
PDGF-BB, and 5′-GATCATTGCTCCTCCTGAGC (sense) and 5′-CACCTT-
CACCGTTCCAGTTT (antisense) for β-actin. The PCR conditions were as
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60 s, 56 °C for 60 s, and 72 °C for 150 s. Products (434 bp forMMP-1, 408 bp for
PDGF-AA, 339 bp for PDGF-BB and 308 bp for β-actin) were resolved on 1.5%
agarose gels and visualized with ethidium bromide.
2.8. Measurement of the generation of reactive oxygen species (ROS)
hCSMCs were treated with N-acetylcysteine for 24 h and washed. The cells
were treated with DCFH diacetate (20 μM), as a probe, at 37 °C for 30 min.
After being washed, cells were stimulated with oxLDL for 30 min, collected,
and resuspended in Hanks' solution. The fluorescence of 2′,7′-dichlorofluo-
rescein resulting from DCFH oxidation was measured with a flow cytometer
(FACSCalibur with CellQuest software, Becton-Dickson Biosciences). The
generation of ROS was expressed as the mean fluorescence intensity of 10,000
cells determined in each sample.
3. Results
The stimulation of hCSMCs with oxLDL (50 μg/ml) for
6–24 h time-dependently induced an increase in MMP-1 protein
in the extracellular medium, as estimated by immunoblotting, as
shown in Fig. 1A. The oxLDL-promoted production of MMP-1
occurred in a dose-dependent manner (10–50 μg/ml), as
confirmed by immunoblotting and zymography and by anFig. 1. Promotion of the production of MMP-1 by oxLDL. (A) hCSMCs were
stimulated with (+) or without (−) oxLDL (50 μg/ml) for the indicated periods.
MMP-1 in the extracellular medium was analyzed by immunoblotting. (B)
hCSMCs were stimulated with various concentrations of oxLDL (10–50 μg/ml)
for 24 h. MMP-1 in the extracellular medium was analyzed by immunoblotting
(a) and zymography (b). (C) Collagenase activity was measured in the
extracellular medium of the cells stimulated with oxLDL as in panel B. (D)
hCSMCs were stimulated with or without native LDL (nLDL, 20 or 50 μg/ml)
or oxLDL (50 μg/ml) for 24 h. MMP-1 in the extracellular medium was
analyzed by immunoblotting.assay for collagenase activity (Fig. 1B and C). In comparison
with oxLDL, native LDL (20 or 50 μg/ml) had a little effect on
the production of MMP-1 in hCSMCs (Fig. 1D). Under our
experimental conditions, there was no significant difference
between amounts of protein recovered from each dish (2×105
cells): for example, 141±3.2 and142±2.8μg/dish (mean±SEM,
n=3), control and oxLDL at 24 h (Fig. 1A), respectively;
138±4, 142±4, 137±3, and 139±3 μg/dish (mean±range,
n=2), control, 20 μg/ml native LDL, 50 μg/ml native LDL, and
oxLDL (Fig. 1D), respectively.
The induction of MMP-1 gene expression is suggested to be
mediated by ERK1/2 in canine fibroblast-like synoviocytes
stimulated with basic calcium phosphate crystals [28]. To
define the intracellular signaling responsible for the oxLDL-
induced production of MMP-1, the possible involvement of
ERK1/2 was examined (Fig. 2). Stimulation with oxLDL
(50 μg/ml) for 5–20 min resulted in an increase in phospho-
rylated ERK1/2. The oxLDL (50 μg/ml, for 10 min)-induced
phosphorylation of ERK1/2 was suppressed dose-dependently
by pretreatment with PD98059 (1–10 μM), an inhibitor of
mitogen-activated protein kinase/ERK kinase. Under the con-
ditions, the oxLDL-induced production of MMP-1 was also
prevented in a manner dependent on the concentration of
PD98059, suggesting that the production of MMP-1 depends
on the activation of ERK1/2.
The activation of ERK1/2 is triggered by the stimulation of
receptors for growth factors such as PDGFR-β in a variety of cell
types including SMCs [29,30]. Since oxLDL has been shown to
induce the activation of PDGFR-β in rabbit arterial SMCs [31],
we examined its involvement in the oxLDL-induced production
of MMP-1 in hCSMCs. Fig. 3A showed that stimulation with
oxLDL (50 μg/ml) for 5–20 min resulted in an increase in
tyrosine-phosphorylated PDGFR-β with a maximal response
10 min after the stimulation, as estimated by immunoprecipita-
tion of PDGFR-β and immunoblotting using antibodies against
PDGFR-β bearing a phospho-tyrosine residue. However, native
LDL (50 μg/ml, for 10 min) was less effective than oxLDL (Fig.
3B). The oxLDL (50 μg/ml, for 10 min)-induced phosphoryla-
tion of PDGFR-β was almost completely suppressed by
pretreatment with genistein (20 μM), an inhibitor of protein
tyrosine kinase (Fig. 3C). Genistein (20 μM) markedly inhibited
the oxLDL-induced increase in MMP-1 protein and phosphory-
lation of ERK1/2 (Fig. 4, A and B). However, genistein even at
20 μMdid not affect the phosphorylation of ERK1/2 (Fig. 4B) or
the production of MMP-1 (data not shown) induced by phorbol
12-myristate 13-acetate (100 nM), a protein kinase C activator,
which activates ERK1/2 independently of the activation of
receptors [32], indicating that genistein had no effect on the
pathways responsible for the ERK1/2-mediated production
of MMP-1. Furthermore, as shown in Fig. 4C, AG1295
(20–100 μM), a specific inhibitor of tyrosine kinase of PDGFR,
dose-dependently suppressed the oxLDL-induced production of
MMP-1, while AG1478 (250 or 500 nM), an inhibitor of
tyrosine kinase of epidermal growth factor receptor, had no
effect (Fig. 4D). We further observed that pretreatment of
oxLDL with the antibodies against PDGF (50 μg/ml) did not
affect the production of MMP-1 induced by the oxLDL (Fig.
Fig. 3. Phosphorylation of PDGFR-β by oxLDL, and inhibition of the
phosphorylation by genistein. (A) hCSMCs were stimulated with oxLDL
(50 μg/ml) for the indicated periods. PDGFR-β (PDGFR) and its tyrosine-
phosphorylated form (p-PDGFR) in the cells were detected by the
immunoprecipitation of PDGFR-β followed by immunoblotting. (B) hCSMCs
were stimulated with or without oxLDL (50 μg/ml) or native LDL (nLDL,
50 μg/ml) for 10 min. PDGFR and p-PDGFR in the cells were detected as in
A. (C) hCSMCs were treated with or without genistein (20 or 50 μM) for 1 h,
and stimulated with (+) or without (−) oxLDL (50 μg/ml) for 10 min. PDGFR
and p-PDGFR in the cells were detected as in A. The degree of the
phosphorylation of PDGFR was estimated by measuring the density of the
PDGFR and p-PDGFR bands (mean±SEM).
Fig. 2. Inhibition of the oxLDL-induced activation of ERK1/2 and production of
MMP-1 by PD98059. (A) hCSMCs were stimulated with (+) or without (−)
oxLDL (50 μg/ml) for the indicated periods. (B) hCSMCs were treated with
various concentrations of PD98059 (1–10 μM) for 1 h, and stimulated with (+)
or without (−) oxLDL (50 μg/ml) for 10 min. ERK1/2 and its phosphorylated
form (p-ERK1/2) in the cells were analyzed by immunoblotting. (C) hCSMCs
were treated with PD98059 as in B, and stimulated with (+) or without (−)
oxLDL (50 μg/ml) for 24 h. MMP-1 in the extracellular medium was analyzed
by immunoblotting. The amount of MMP-1 was estimated by measuring the
density of the MMP-1 band (mean±SEM).
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involved in the promotion of MMP-1 production induced by
oxLDL.
oxLDL has been shown to induce the production of
PDGF-AA in canine SMCs prepared from prosthetic vascular
grafts but not in canine aortic SMCs [33]. In the present
study, oxLDL (50 μg/ml) promoted the expression of MMP-1
mRNA, but did not affect the expression of PDGF-AA
mRNA or PDGF-BB mRNA in hCSMCs (Fig. 5A).
Furthermore, although hCSMCs were stimulated with
oxLDL (50 μg/ml) in the presence of antibodies against
PDGF (100 μg/ml), the oxLDL-induced production of MMP-
1 was not affected as estimated by zymography (Fig. 5B). As
a control experiment, the antibodies impaired the production
of MMP-1 induced by PDGF-BB (Fig. 5C).
The activation of ERK1/2 has been shown to partially
depend on the generation of ROS in native LDL-stimulated
human umbilical vein SMCs [34]. Our recent report showed
that oxLDL induced the generation of ROS in rat mesangial
cells [35]. However, we confirmed that although oxLDL
stimulated the generation of ROS in hCSMCs, inhibition ofthe ROS generation by the antioxidant N-acetylcysteine had
no effect on the oxLDL-induced activation of ERK1/2 or
production of MMP-1 (Fig. 6).
We further examined whether oxidized lipids, such as 4-
HNE and oxysterols, are involved in the production of
MMP-1 in hCSMCs. The results shown in Fig. 7A indicate
that stimulation with 4-HNE (2–20 μM) dose-dependently
induced the production of MMP-1 (for 24 h) with the
preceding phosphorylation of ERK1/2 (for 10 min). How-
ever, 7-ketocholesterol (10 μM), 25-hydroxycholesterol
(10 μM), 13-hydroxyoctadecadienoic acid (5 μM), or
lysophosphatidylcholine (5 μM) had no effect on the
production of MMP-1 (Fig. 7D). Pretreatment with
PD98059 (2–10 μM) dose-dependently suppressed the 4-
HNE (10 μM)-induced production of MMP-1 as well as
phosphorylation of ERK1/2 (Fig. 7B and C). In addition to
oxLDL, 4-HNE (10 μM, for 10 min) induced tyrosine
phosphorylation of PDGFR-β, which was significantly
Fig. 5. Expression of mRNA for MMP-1 and PDGF in oxLDL-stimulated
hCSMCs. (A) hCSMCs were stimulated with (+) or without (−) oxLDL
(50 μg/ml) for 12 h. After the extraction of total RNA, mRNA for MMP-1,
β-actin, PDGF-AA, and PDGF-BB was analyzed by RT-PCR. (B) hCSMCs
were stimulated with (+) or without (−) oxLDL (50 μg/ml) for 24 h in the
presence (+) or absence (−, control IgG) of anti-human PDGF antibodies
(anti-PDGF Ab, 100 μg/ml). MMP-1 in the extracellular medium was
analyzed by zymography. (C) hCSMCs were stimulated for 24 h with (+) or
without (−) PDGF-BB (10 ng/ml) that had been incubated with (+) or without
(−, control IgG) anti-human PDGF antibodies (final concentration 100 μg/ml)
for 3 h. MMP-1 was analyzed as in panel B.
Fig. 6. Effects of N-acetylcysteine on the oxLDL-induced generation of ROS,
activation of ERK1/2, and production of MMP-1. (A) hCSMCs were treated
with or without N-acetylcysteine (NAC, 10 mM) for 24 h and washed. The cells
were treated with DCFH diacetate (20 μM) for 30 min. After being washed, cells
were stimulated with or without oxLDL (50 μg/ml) for 30 min. The fluorescence
of 2′,7′-dichlorofluorescein resulting from DCFH oxidation was measured. (B)
hCSMCs were treated with or without NAC (5 or 10 mM) for 24 h. After being
washed, the cells were stimulated with or without oxLDL (50 μg/ml) for 10 min
for the detection of phosphorylated ERK1/2 (p-ERK1/2) or for 24 h for the
detection of MMP-1. ERK1/2 and p-ERK1/2 in the cells and MMP-1 in the
extracellular medium were analyzed by immunoblotting.
Fig. 4. Inhibition of the oxLDL-induced production of MMP-1 by genistein
and AG1295. (A) hCSMCs were treated with or without genistein (20 or
50 μM) for 1 h, and stimulated with (+) or without (−) oxLDL (50 μg/ml) for
24 h. MMP-1 in the extracellular medium was analyzed by immunoblotting.
The amount of MMP-1 was estimated by measuring the density of the MMP-1
band (mean±SEM). (B) hCSMCs were treated with or without genistein (10 or
20 μM) for 1 h, and stimulated with (+) or without (−) oxLDL (50 μg/ml) or
phorbol 12-myristate 13-acetate (PMA, 100 nM) for 10 min. ERK1/2 and its
phosphorylated form (p-ERK1/2) in the cells were analyzed by immunoblotting.
(C) hCSMCs were treated with or without AG1295 (20–100 μM) for 1 h, and
stimulated with (+) or without (−) oxLDL (50 μg/ml) for 24 h. (D) hCSMCswere
treated with or without AG1478 (250 or 500 nM) for 1 h, and stimulated with (+)
or without (−) oxLDL (50 μg/ml) for 24 h.
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AG1295 (100 μM) (Fig. 8A). Under the conditions, genistein
(10 or 20 μM) and AG1295 (20–100 μM) prevented the 4-
HNE (10 μM)-induced production of MMP-1 in a dose-
dependent manner (Fig. 8B and C). We confirmed that
Fig. 8. Inhibition of the 4-HNE-induced phosphorylation of PDGFR-β and
production of MMP-1 by genistein and AG1295. (A) hCSMCs were treated with
or without genistein (20 μM) or AG1295 (100 μM) for 1 h, and stimulated with
(+) or without (−) 4-HNE (10 μM) for 10 min. PDGFR-β (PDGFR) and its
tyrosine-phosphorylated form (p-PDGFR) in the cells were detected by the
immunoprecipitation of PDGFR-β followed by immunoblotting. (B) hCSMCs
were treated with or without genistein (GEN, 10 or 20 μM) for 1 h, and
stimulated with (+) or without (−) 4-HNE (10 μM) for 24 h. MMP-1 in the
extracellular medium was analyzed by immunoblotting. (C) hCSMCs were
treated with or without AG1295 (20–100 μM) for 1 h, and stimulated with (+) or
without (−) PDGF-BB (10 ng/ml) for 24 h. MMP-1 was analyzed as in panel B.
Fig. 7. Inhibition of the 4-HNE-induced activation of ERK1/2 and production of
MMP-1 by PD98059. (A) hCSMCs were stimulated with various concentrations
of 4-HNE (2–20 μM) for 10 min for the detection of phosphorylated ERK1/2 (p-
ERK1/2) or for 24 h for the detection of MMP-1. ERK1/2 and p-ERK1/2 in the
cells and MMP-1 in the extracellular medium were analyzed by immunoblot-
ting. (B and C) hCSMCs were treated with various concentrations of PD98059
(PD, 2–10 μM) for 1 h, and stimulated with (+) or without (−) 4-HNE (10 μM)
for 10 min (B) or 24 h (C). ERK1/2 and p-ERK1/2 in the cells (B) and MMP-1 in
the extracellular medium (C) were analyzed by immunoblotting. (D) hCSMCs
were stimulated with (b–e) or without (a) 7-ketocholesterol (b, 10 μM), 25-
hydroxycholesterol (c, 10 μM), 13-hydroxyoctadecadienoic acid (d, 5 μM), or
lysophosphatidylcholine (e, 5 μM) for 24 h. MMP-1 was analyzed as in panel C.
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induced by PDGF-BB (10 ng/ml) (Fig. 8D).
4. Discussion
The formation of atherosclerotic lesions is a complex
process, which is mediated by numerous cellular responses in
SMCs and macrophages stimulated with cytokines, oxLDL, or
bioactive oxidized lipids, such as 4-HNE and oxysterols.
Among the cellular responses, the production of collagenases
including MMP-1 is a critical event responsible for the
progression of atherosclerosis, because collagenases are the
only MMPs that can catalyze the degradation of native collagen,
a major structural component of atherosclerotic lesions, being
involved in the migration of vascular SMCs into the intima and
the rupture of plaques. The expression of MMP-1 is increased in
human atherosclerotic plaques, where SMCs [14,15] and
macrophages [14,16] are colocalized, although it is unclear
whether MMP-1 is produced by the atheroma-associated cells in
response to oxLDL and bioactive oxidized lipids. The presentstudy demonstrated that oxLDL or 4-HNE accelerated the
production of MMP-1 in hCSMCs. Thus, it is possible that the
activation of SMCs by oxLDL and 4-HNE is involved in the
production of MMP-1 at atherosclerotic lesions.
With regard to the mechanisms responsible for the production
of MMP-1 elicited by oxLDL and 4-HNE, we showed here that
they induced the activation of ERK1/2, inhibition of which
resulted in a suppression of MMP-1 production, suggesting the
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consistent with the notion reported recently [36]. The activation
of ERK1/2 is triggered by the stimulation of several types of
receptors. PDGFR-β has been shown to be one of the receptors
involved in the activation of ERK1/2 in SMCs [29,30]. The
present study demonstrated that stimulation of hCSMCs with
oxLDL and 4-HNE induced tyrosine phosphorylation of
PDGFR-β. Furthermore, inhibition by genistein of the phos-
phorylation of PDGFR-β occurred in parallel with a suppression
of ERK1/2 activation in oxLDL-stimulated hCSMCs. It is
possible that the activation of PDGFR-β is related to the
activation of ERK1/2, as suggested in guinea-pig airway [29]
and chick gizzard [30] SMCs. oxLDL has been shown to activate
PDGFR-β in an early phase within 1 h that is independent of
ROS and in a late phase at 5 h that is dependent on ROS in rabbit
arterial SMCs [31]. Consistent with the early phase, we
demonstrated that oxLDL and 4-HNE induced tyrosine phos-
phorylation of PDGFR-β relatively quickly (within 20 min) in
hCSMCs. In the present study, we found that under conditions
where the oxLDL- and 4-HNE-induced activation of PDGFR-β
was suppressed by AG1295 and genistein, the accelerated
production of MMP-1 was significantly prevented. Our results
suggest that the activation of PDGFR-β is involved in the
production of MMP-1 in response to oxLDL and 4-HNE. It has
been proposed that the activation by oxLDL of PDGFR-β is
ascribable to the direct interaction of the receptor with the 4-
HNE that diffuses from oxLDL particles to plasma membranes
to form adducts with the receptor [31]. In addition to PDGFR-β,
epidermal growth factor receptor is reported to be activated by
oxLDL in bovine aortic SMCs and human CRL-1998
endothelial cells [37]. However, the contribution of epidermal
growth factor receptor seems unlikely, because the oxLDL-
accelerated production of MMP-1 in hCSMCs was not affected
by AG1478, an inhibitor of the receptor. Based on the present
findings, we suggest that the oxLDL- and 4-HNE-induced
activation of PDGFR-β is involved, at least in part, in the
initiation of intracellular signaling leading to the production of
MMP-1.
A previous report showed that oxLDL induces the
secretion of PDGF-AA in canine SMCs prepared from
prosthetic vascular grafts [33]. This finding raises a possibility
that PDGF generated endogenously might be involved in the
oxLDL-induced production of MMP-1. Under our experi-
mental conditions, however, oxLDL seems to scarcely
promote the expression of PDGF-AA mRNA or PDGF-BB
mRNA despite an increase in MMP-1 mRNA. Similarly, in
canine aortic SMCs, oxLDL does not induce the production
of PDGF-AA [33]. Furthermore, the oxLDL-induced produc-
tion of MMP-1 was not affected under conditions where
hCSMCs were stimulated with oxLDL in the presence of anti-
PDGF antibodies. Considering these findings, it seems
unlikely that autocrine effects of PDGF generated endogen-
ously are involved in the oxLDL-induced production of
MMP-1 in hCSMCs.
In summary, we demonstrated here that stimulation of
hCSMCs with oxLDL and 4-HNE induced the production of
MMP-1 with the preceding phosphorylation of PDGFR-β andERK1/2. The present results suggest that the acceleration of
MMP-1 production depends on the activation of PDGFR-β and
ERK1/2.
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